Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.

ABSTRACT: Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.

SUBMITTER: Sanchez L 

PROVIDER: S-EPMC4929758 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature